GlassScriptPhysician profile
Melinda Webb
NPI 1225268931
$1,940.76
in general payments reported to CMS, 2019-2025
24 companies · $227 in 2025
The $227 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $697 · 2022: $846 · 2023: $90.94 · 2024: $79.01 · 2025: $227.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $397.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $397.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $333.05 | 2021-2023 | Nucala |
| Astrazeneca Pharmaceuticals LP | $284.77 | 2021-2023 | Tezspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $196.11 | 2021-2022 | |
| Genzyme Corporation | $165.37 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $111.80 | 2021-2022 | |
| Vanda Pharmaceuticals INC. | $97.76 | 2024-2025 | Fanapt, Hetlioz |
| Mylan Specialty L.P. | $68.13 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $66.35 | 2021-2023 | Dupixent |
| Abbvie INC. | $62.97 | 2025 | |
| Janssen Pharmaceuticals, INC | $58.44 | 2021-2022 | |
| Actelion Pharmaceuticals US, INC. | $55.45 | 2022 | |
| Jazz Pharmaceuticals INC. | $52.06 | 2021 | |
| United Therapeutics Corporation | $48.00 | 2021-2023 | Tyvaso |
| Harmony Biosciences LLC | $45.36 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $43.61 | 2021-2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $43.41 | 2025 | |
| Baxter Healthcare | $38.89 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $35.60 | 2024-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Philips North America LLC | $34.21 | 2021 | |
| Braeburn INC. | $33.13 | 2024-2025 | Brixadi |
| Pfizer INC. | $20.66 | 2022 | |
| Indivior INC. | $19.79 | 2025 | Sublocade |
| Teva Pharmaceuticals USA, INC. | $13.65 | 2025 | Austedo Xr |
| Ani Pharmaceuticals, INC. | $12.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melinda Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.